1 is a ubiquitous Ca 2ϩ -binding protein that regulates as many as 80 target proteins, many of which are enzymes whose activity is stimulated by CaM in a Ca 2ϩ -dependent manner (1, 2) . The human genome contains three CaM genes, which are independently regulated, but encode exactly the same protein sequence (3) . On the other hand, plants express several CaM isoforms with distinct sequences (4, 5) . For example, the soybean genome contains at least five CaM genes, which encode four distinct protein sequences (6) . The soybean CaMs are denoted SCaM-1 to SCaM-5. SCaM-1, SCaM-2, and SCaM-3 are similar to mammalian CaMs, whereas SCaM-4 and SCaM-5 are quite different. For example, SCaM-1 and human CaM (hCaM) are 90.5% identical, with nine conservative and five non-conservative substitutions in the 148-amino acid protein, whereas SCaM-4 and hCaM are 77% identical, with 19 conservative and 15 non-conservative substitutions (see Fig. 1 ). As might be expected, SCaM-1 behaves very similarly to hCaM in activation of a variety of target enzymes, whereas SCaM-4 differs significantly (6 -9) . For example, SCaM-1 activates smooth muscle myosin light chain kinase (MLCK) with the same K CaM value (concentration required for half-maximal activation) as hCaM, whereas SCaM-4 does not activate MLCK (9) . On the other hand, SCaM-4 activates nitric-oxide synthase, whereas SCaM-1 does not (8) . Other CaM target enzymes, e.g. cyclic nucleotide phosphodiesterase and Ca 2ϩ /CaM-dependent protein kinase II, are activated by both SCaM-1 and SCaM-4 (6, 9) .
MLCK plays a critical role in the regulation of smooth muscle contraction and non-muscle motile processes such as cytokinesis, cell migration, transepithelial permeability, and fibroblast contraction (10) . A variety of contractile stimuli elicit an increase in the cytosolic free [Ca 2ϩ ] either by entry from the extracellular space via voltage-gated or receptor-operated Ca 2ϩ channels or by release from intracellular stores (principally the sarcoplasmic reticulum) via inositol 1,4,5-trisphosphate receptors or ryanodine receptors (11, 12) . The popular current theory of the mechanism of activation of MLCK by CaM involves the binding of Ca 2ϩ to the four Ca 2ϩ -binding sites of CaM, which then interacts with and activates MLCK that is anchored via its N-terminal tail to actin (13) (14) (15) (16) . (Ca 2ϩ ) 4 ⅐CaM activates MLCK by inducing a conformational change that involves removal of the autoinhibitory domain from the active site, allowing access to the myosin substrate (11, 17) . Activated MLCK phosphorylates the 20-kDa light chains of myosin II at Ser 19 , triggering cross-bridge cycling and the development of force (11, 12) .
The availability of the different plant CaM isoforms provides very useful tools for studying the mechanism of activation of MLCK and other CaM target enzymes. In this work, we exploited the existence of distinct plant isoforms of CaM, specifically SCaM-1 and SCaM-4 as well as chimeric and site-specific mutants of SCaM-1, to further our understanding of the mechanism whereby CaM activates MLCK in a Ca 2ϩ -dependent manner. We showed earlier that SCaM-1 behaves exactly like CaM in activation of MLCK, whereas SCaM-4 fails to activate the kinase (9) . Here we show that SCaM-4 behaves as a CaM antagonist, confirming earlier findings that binding of CaM to MLCK and activation of the enzyme are distinct events (18) . Using a mutagenesis strategy based on the sequence differences between SCaM-4 and SCaM-1, we provide evidence that Lys 30 and Gly 40 play a key role in the activation process. Examination of the three-dimensional structures of free CaM and CaM bound to the CaM-binding domain of MLCK reveals that these side chains lie within a newly formed surface on CaM that is created as the protein binds to MLCK. Two mechanisms could explain these results: (i) saturation of the Ca 2ϩ -binding sites of CaM induces a conformational change in MLCK that permits interactions between this newly created surface on CaM and an unspecified region of the kinase distinct from the well known CaM-binding site, and these interactions are required for removal of the autoinhibitory domain from the active site; or (ii) the newly formed surface is required to stabilize the conformation of (Ca 2ϩ ) 4 ⅐CaM necessary for MLCK activation.
EXPERIMENTAL PROCEDURES
Materials-SCaM-1 and SCaM-4 were expressed in Escherichia coli and purified as previously described (6, 7) . SCaM-1 mutants (K30E, M36I, G40D, and the triple mutant K30E/M36I/G40D, denoted SCaM-1-TM) were constructed from wild-type SCaM-1 cDNA by primer-based site-directed mutagenesis using the QuikChange site-directed mutagenesis kit (Stratagene). Mutations were verified by DNA sequence analysis. The cDNA encoding the SCaM-4111 chimera was generously provided by Dr. Moo Je Cho (Department of Biochemistry, Plant Molecular Biology and Biotechnology Research Center, Gyeongsang National University, Chinju, Korea). Myosin (19) and MLCK (20) were purified from chicken gizzard smooth muscle. The 20-kDa light chain of myosin (LC 20 ) was isolated from purified myosin using a modification of the method of Hathaway and Haeberle (21) as described by Weber et al. (22) . MLC-(11-23), a synthetic peptide substrate of MLCK corresponding to residues 11-23 of LC 20 (KKRPQRATSNVFA), was synthesized in the Peptide Synthesis Core Facility at the University of Calgary. The purity of the peptide was Ͼ95% as determined by analytical highperformance liquid chromatography and amino acid analysis, and its concentration was determined by quantitative amino acid analysis. Bovine brain CaM (bCaM) was purchased from Sigma. [␥-32 P]ATP (Ͼ5000 Ci/mmol) was purchased from Amersham Biosciences, Inc. Monoclonal anti-CaM antibody was purchased from Upstate Biotechnology, Inc. and used at a concentration of 1 g/ml. This antibody, which was raised against a synthetic peptide corresponding to the C terminus of CaM (residues 128 -148), did not recognize SCaM-1 or SCaM-4. Polyclonal anti-CaM antibody was purchased from Santa Cruz Biotechnology and used at 1:200 dilution. This antibody, which was raised against full-length CaM, cross-reacted with both SCaM-1 and SCaM-4. Polyclonal anti-LC 20 antibody (22) was used at 1:1000 dilution. Horseradish peroxidase-conjugated anti-mouse IgG (Chemicon International, Inc.) and horseradish peroxidase-conjugated anti-rabbit IgG (Roche Molecular Biochemicals) were used as the secondary antibodies at a dilution of 1:10,000. Triton X-100, Tween 20, and Tween 80 were purchased from Fisher, and trifluoperazine (TFP) was from ICN Biomedicals, Inc.
Buffer Compositions-HEPES/Tyrode's buffer contained 137.0 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl 2 , 1.8 mM CaCl 2 , 10 mM HEPES, and 5.6 mM glucose (pH 7.4). Ca 2ϩ -free HEPES/Tyrode's buffer was composed of 140.6 mM NaCl, 2.7 mM KCl, 1.0 mM MgCl 2 , 10 mM HEPES, and 5.6 mM glucose (pH 7.4). Buffer A comprised 30 mM TES, 0.5 mM dithiothreitol, 50 mM KCl, 5 mM K 2 EGTA, and 150 mM sucrose (pH 7.4). pCa 9 solution contained 20 mM TES, 4 mM K 2 EGTA, 5.83 mM MgCl 2 , 7.56 mM potassium propionate, 1 mM NaN 3 , 3.9 mM Na 2 ATP, 0.5 mM dithioerythritol, 16.2 mM phosphocreatine, and 15 units/ml creatine kinase (pH 6.9). pCa 4.5 solution was composed of 20 mM TES, 4 mM CaEGTA, 5.66 mM MgCl 2 , 7.53 mM potassium propionate, 1 mM NaN 3 , 3.9 mM Na 2 ATP, 0.5 mM dithioerythritol, 16.2 mM phosphocreatine, and 15 units/ml creatine kinase (pH 6.9).
MLCK Assays-MLCK activity was assayed using either MLC- (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) or LC 20 as substrate as follows. With MLC-(11-23) as substrate, MLCK (2 g/ml) was incubated at 30°C for 10 min with 0.1 mM MLC- (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) Reactions were started by addition of radiolabeled ATP and stopped by spotting 20 l of the reaction mixture on squares (1 ϫ 1 cm) of phosphocellulose P-81 paper (Whatman) and immersing in a beaker containing 0.5% (v/v) H 3 PO 4 . P-81 papers were washed with 3 ϫ 500 ml of 0.5% (v/v) H 3 PO 4 (5 min each) and once with 500 ml of acetone (5 min) and air-dried, and 32 P incorporation was quantified by Cerenkov counting. Independent experiments indicated that the phosphorylation of MLC- (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) and LC 20 was linear for at least 15 min under the conditions used. The concentrations of stock solutions of LC 20 were determined by quantification of maximal phosphorylation levels by incorporation of radiolabeled ATP and ureaglycerol gel electrophoresis (22) . The specific activity of MLCK was determined to be 1.1 Ϯ 0. tively against deionized water, and the free [Ca 2ϩ ] was controlled by adding a given amount of CaCl 2 to 200 mM MOPS (pH 7.0), 90 mM KCl, 2 mM EGTA, and 3 mM MgCl 2 as previously described (23) . Other conditions for these assays were as follows: 0.5 nM MLCK, 10 M LC 20 , 0.2 mM [␥-
32 P]ATP (ϳ150 cpm/pmol), and 2 M CaM. The Ca 2ϩ stock solutions and Ca 2ϩ buffer were calibrated by the Ca 2ϩ -dependent increase in Quin-2 fluorescence occurring at pCa 6.86 with a Hill coefficient of 1.0.
Tension Measurements-Male Sprague-Dawley rats (300 -350 g) were killed by halothane inhalation and decapitation according to a research protocol consistent with the standards of the Canadian Council on Animal Care and approved by the Animal Care Committee, Faculty of Medicine, University of Calgary. Excess adventitia and adipose tissue were dissected free from the tail artery in Ca 2ϩ -free HEPES/ Tyrode's buffer. Segments of rat tail artery (RTA) were placed over a 0.31-mm needle and passed back and forth 40 times to remove the endothelium, prior to cutting into 6 ϫ 1.5-mm helical strips and mounting on a Grass Model FTO3C isometric force transducer connected to a PowerLab eight-channel recording device (ADInstruments). Strips were mounted on the transducer with a resting tension of 0.45 g and incubated for 20 min in HEPES/Tyrode's buffer (bath volume ϭ 0.8 ml). Tissues were stimulated three times with HEPES/Tyrode's buffer containing 87 mM KCl (the increase in [KCl] was balanced by a decrease in [NaCl]) with a 20-min interval of relaxation in Ca 2ϩ -free HEPES/ Tyrode's buffer to achieve a stable contractile response to depolarization. Only the third K ϩ -induced contraction is shown in Fig. 5 . Following a 10-min relaxation period after removal of K ϩ , muscle strips were incubated for 5 min in Ca 2ϩ -free HEPES/Tyrode's buffer and for 5 min in Buffer A and subsequently skinned (demembranated) by incubation for 2 h in Buffer A containing 1% Triton X-100. Skinned tissues were washed (3 ϫ 5 min) in pCa 9 solution, followed by 30 min in pCa 4.5 solution to elicit a sustained Ca 2ϩ -induced contraction. Skinned muscle strips were then relaxed by incubation in pCa 9 solution for 10 min and washed (2 ϫ 5 min) in pCa 9 solution. A second Ca 2ϩ -induced contraction was elicited as described above. During the plateau phase of this contraction (30 min after addition of Ca 2ϩ ), TFP (0.4 mM) was added; and consequently, the muscle slowly relaxed. When force had declined to base line (within 30 min), tissues were washed (8 ϫ 5 min) in pCa 9 solution. Transfer to pCa 4.5 solution for 20 min then failed to elicit a contractile response. After returning to pCa 9 solution (2 ϫ 5 min), the bathing solution was changed to the appropriate CaM isoform or mutant (1.87 M) in pCa 9 solution or to pCa 9 solution alone; and 15 min later, any unbound CaM was washed out by incubation (3 ϫ 5 min) in pCa 9 solution. Muscle strips were then incubated in pCa 4.5 solution for 30 min, followed by pCa 9 solution (3 ϫ 5 min). Fig. 1 shows a comparison of the amino acid sequences of hCaM and two of the isoforms of soybean CaM, SCaM-1 and SCaM-4 (6). hCaM and SCaM-1 are 90.5% identical, and hCaM and SCaM-4 are 77% identical. We demonstrated previously that SCaM-1 is as potent as bCaM in activation of smooth muscle MLCK and activates MLCK to the same extent as bCaM: half-maximal activation of MLCK (K CaM ) occurred at 1.7 nM bCaM with a Hill coefficient of 1.1 and at 1.8 nM SCaM-1, also with a Hill coefficient of 1.1, whereas SCaM-4 caused very little activation of MLCK even at 1 M ( Fig. 2A) (9) . Similar results were obtained in assays using MLC-(11-23) as substrate; in this case, half-maximal activation of MLCK occurred at 8 nM bCaM and 5 nM SCaM-1, and no activation was observed with SCaM-4. Comparison of the amino acid sequences of SCaM-1 and SCaM-4 indicates that substitutions are scattered throughout the molecule, but more (five conservative and seven non-conservative) are found in the N-terminal domain (residues 1-46) (Fig. 1) . Therefore, a chimera composed of the first Ca 2ϩ -binding domain of SCaM-4 (Ala 1 -Leu 48 ) and the second, third, and fourth Ca 2ϩ -binding domains of SCaM-1 (Gln 49 -Lys 148 ) was expressed and purified. This chimera (denoted SCaM-4111), like SCaM-4, effected little activation of MLCK ( Fig. 2A) , indicating that substitutions in the N-terminal Ca 2ϩ -binding domain of SCaM-1 are responsible for the loss of activation by SCaM-4.
RESULTS

Effects of Plant Isoforms of CaM and Site-specific Mutants on MLCK Activity-
To identify the specific amino acids in the N-terminal domain that are required for activation of MLCK, a triple mutant was prepared in which Lys 30 , Met 36 , and Gly 40 of SCaM-1 were replaced by Glu, Ile, and Asp, respectively, as found in SCaM-4. This mutant (designated SCaM-1-TM) was a weak activator of MLCK, with a K CaM of 66 nM and V max 43% that of MLCK activated by bCaM or SCaM-1 ( Fig. 2A) . To determine which of these residues are involved in activation of MLCK, individual site-specific mutants were expressed and purified, and their effects on MLCK activity were assayed (Fig. 2B) . M36I activated MLCK with K CaM (1.4 nM) and V max values similar to those observed with bCaM or SCaM-1. On the other hand, both the K30E and G40D mutants of SCaM-1 were relatively weak activators of MLCK, with K CaM values of 15 and 26 nM, respectively, and V max values 57 and 68%, respectively, that of MLCK activated by bCaM or SCaM-1 (Fig. 2B) . These results indicate that Lys 30 and Gly 40 of bCaM and SCaM-1 play important roles in the activation of MLCK.
Ca 2ϩ Dependence of Activation of MLCK by Plant CaMs and Mutants-The
Ca 2ϩ dependence of activation of MLCK by CaM and SCaM-1 was very similar, with half-maximal activation at pCa 6.13 and 6.20, respectively (Fig. 3A) . The triple mutant of SCaM-1, which only partially activated MLCK, required a much higher [Ca 2ϩ ] for activation, with half-maximal activation at pCa 5.0 (Fig. 3A) , suggesting that these mutations affect the affinity for Ca 2ϩ . The single mutation M36I had no significant effect on the Ca 2ϩ dependence of activation of MLCK by this SCaM-1 mutant, which half-maximally activated MLCK at pCa 6.14, whereas both K30E and G40D mutations increased markedly the [Ca 2ϩ ] required for half-maximal activation of MLCK (Fig. 3B ). In the case of the K30E mutant, half-maximal activation was achieved at pCa 5. 7. In the case of the G40D mutant, although a plateau was not reached, half-maximal activation occurred at pCa 3.6 because, as in every case, MLCK activity decreased above the free [Ca 2ϩ ] of 0.5-1 mM (data not shown).
SCaM-4 Binds to, but Does Not Activate, MLCK-
The lack of activation of MLCK by SCaM-4 could be due to an inability to bind to the kinase or an inability to activate the kinase despite binding to it. These possibilities were addressed in competition assays with bCaM and SCaM-1. SCaM-4 (100 nM), which failed to activate MLCK ( Fig. 2A) , shifted the CaM activation curve for MLCK significantly to the right. When these data were analyzed as Lineweaver-Burk plots, the slope, but not the y intercept, was affected by SCaM-4 (Fig. 4A) . This indicates that SCaM-4 does indeed bind to MLCK and is a competitive inhibitor of the kinase with respect to bCaM. Addition of SCaM-4 to a fixed concentration of bCaM (1.7 nM) or SCaM-1 (1.8 nM), sufficient for half-maximal activation of MLCK, caused a concentration-dependent inhibition of MLCK activity, confirming that SCaM-4 competitively inhibits MLCK activation by bCaM or SCaM-1 (Fig. 4B) . A K i of 31 nM and a Hill coefficient of 1.1 were obtained for inhibition of bCaM-mediated activation of MLCK. Similar values (K i ϭ 33 nM and Hill coefficient ϭ 1.1) were determined for SCaM-4-mediated inhibition of SCaM-1-induced activation of MLCK (Fig. 4B) . The fact that SCaM-4 binds to MLCK is consistent with the fact that, of the 12 substitutions in the N-terminal domain of SCaM-4 compared with CaM, only two of these side chains are involved in interaction with the CaM-binding domain, i.e. Glu 11 and Met 36 (24) , which are conservatively substituted in SCaM-4 (Asp and Ile, respectively). The SCaM-4111 chimera was a less potent inhibitor of bCaM activation of MLCK, with a K i of 230 nM and a Hill coefficient of 1.1 (Fig. 4B) .
Effects of Plant CaMs and Mutants on Contraction of Skinned, CaM-depleted Vascular Smooth
Muscle-CaM was selectively removed from Triton X-100-skinned RTA smooth muscle by treatment with the CaM antagonist TFP (Fig. 5) . Addition of TFP at the peak of a Ca 2ϩ -induced contraction caused a reduction in tension to basal levels. The (Ca 2ϩ ) 4 ⅐CaM⅐TFP 2 complex was then removed, and the tissue was washed extensively in the absence of Ca 2ϩ . Subsequent addition of Ca 2ϩ failed to induce myosin phosphorylation or to evoke a contractile response due to the absence of CaM. Near   FIG. 6. bCaM, SCaM-1 , and SCaM-4 bind to skinned, CaM-depleted vascular smooth muscle in the absence of Ca 2؉ . A, Western blotting with monoclonal anti-CaM antibody. RTA strips of equal dimensions (1.5 ϫ 6 mm) were snap-frozen in a Ϫ70°C acetone solution containing 10% trichloroacetic acid and 10 mM dithiothreitol, washed three times with a Ϫ70°C acetone solution containing 10 mM dithiothreitol, and lyophilized. Strips were placed in 200 l of SDS gel sample buffer (39) containing 5% ␤-mercaptoethanol, boiled for 5 min, and mixed for 2 h at room temperature. Samples (30 l/lane) were subjected to SDS gel electrophoresis (15% acrylamide). Subsequent blotting procedures were as previously described (22) . Treatment of Triton X-100-skinned RTA with TFP in the presence of Ca 2ϩ removed essentially all endogenous CaM (lane 2). Addition of bCaM in the absence of Ca complete extraction of tissue CaM was confirmed by Western blotting (Fig. 6A, lane 2) (25) . Following the removal of endogenous CaM, bCaM (Fig. 5a ), SCaM-1 (Fig. 5b) , SCaM-4 ( Fig.  5c ), or no CaM (Fig. 5d) was added to the bathing medium in the absence of Ca 2ϩ , and excess unbound protein was washed out at pCa 9. The [Ca 2ϩ ] was then increased to pCa 4.5. bCaM (Fig. 5a ) and SCaM-1 (Fig. 5b) both evoked a contraction in the presence of Ca 2ϩ , but SCaM-4 ( Fig. 5c) failed to do so. Cumulative data shown in Fig. 5e indicate the change in tension elicited by (i) K ϩ depolarization of intact tissue; (ii) addition of Ca 2ϩ to Triton X-100-skinned muscle strips; (iii) Ca 2ϩ addition following the removal of endogenous CaM by TFP; and (iv-vii) Ca 2ϩ addition following the binding, in the absence of Ca 2ϩ , of bCaM, SCaM-1, SCaM-4, or no CaM, respectively. These results are consistent with the effects of these proteins on the activity of purified MLCK (see above). Western blotting confirmed that exogenous bCaM, SCaM-1, and SCaM-4 all bound to the skinned smooth muscle preparation in the absence of Ca 2ϩ (Fig. 6 ).
As shown in Fig. 7a , SCaM-1-TM caused a small and slow contraction, consistent with its very weak activation of MLCK. Subsequent addition of bCaM increased force, albeit slowly, probably due to competition between bCaM and SCaM-1-TM for binding to MLCK. On the other hand, the site-specific mutants K30E, M36I, and G40D were all capable of supporting Ca 2ϩ -induced contraction (Fig. 7, b-d) , consistent with their ability to activate MLCK to a reasonable level. In these instances, subsequent addition of bCaM had no effect. Based on the results of Figs. 2B and 3B, it might be assumed that the K30E and G40D mutants would be relatively poor activators of contraction. However, it is important to note that there is not a linear relationship between force and LC 20 phosphorylation. In Triton X-100-skinned RTA smooth muscle, maximal tension is achieved at 0.15-0.2 mol of P i /mol of LC 20 (26) . Cumulative data shown in Fig. 7e indicate the change in tension elicited by (i) K ϩ depolarization of intact tissue; (ii) addition of Ca 2ϩ to Triton X-100-skinned muscle strips; and (iii-vii) Ca 2ϩ addition following the replacement of endogenous CaM by SCaM-1-TM, K30E, M36I, G40D, or bCaM, respectively. The open bars indicate that subsequent addition of bCaM where indicated increased the force response to SCaM-1-TM, but not to K30E, M36I, or G40D.
Additional experiments were carried out with Triton X-100-skinned porcine coronary arterial smooth muscle depleted of CaM by treatment with TFP in the presence of Ca 2ϩ . These results can be summarized as follows. SCaM-4 (10 M) failed to elicit a contractile response in the presence of Ca 2ϩ , whereas SCaM-1 (1 M) evoked a maximal contractile response, which was reversed by TFP. If SCaM-1 (1 M) was added to CaMdepleted porcine coronary artery in the presence of SCaM-4 (10 M), the magnitude of the Ca 2ϩ -induced contraction and the rate of contraction were significantly reduced, consistent with competition between SCaM-1 and SCaM-4 for binding to the same sites. If SCaM-1 (1 M) was added first in the presence of Ca 2ϩ to initiate a contraction and SCaM-4 (10 M) was added at the plateau of force development in the continued presence of Ca 2ϩ , SCaM-4 did not induce relaxation, consistent with very tight binding of SCaM-1, as demonstrated previously for bCaM (25) . 4 ⅐CaM, and (Ca 2؉ ) 4 ⅐CaM complexed with the CaM-binding domain of MLCK. A, the threedimensional structure of apoCaM determined by NMR spectroscopy (27) 4 ⅐CaM determined by x-ray crystallography (28) . The same residues as in A are indicated. Ca 2ϩ ions are in green. C, the three-dimensional structure of the complex of (Ca 2ϩ ) 4 ⅐CaM with a peptide corresponding to the CaM-binding domain of MLCK determined by x-ray crystallography (24) . The ␣-helical MLCK peptide is seen end-on in the center of the structure. 30 and Gly 40 of CaM play a key role in activation of MLCK. The three-dimensional structures of several forms of CaM have been determined at high resolution by x-ray crystallography and NMR spectroscopy; these include apoCaM (27) , Ca 2ϩ -saturated CaM (28) , and a complex of (Ca 2ϩ ) 4 ⅐CaM with a peptide corresponding to the CaM-binding domain of MLCK (24) (Fig. 8) . The binding of Ca 2ϩ to CaM induced a significant conformational change (Fig. 8, compare A and B) , but the molecule retained its characteristic dumbbell shape. In the presence of the CaM-binding peptide of MLCK, however, (Ca 2ϩ ) 4 ⅐CaM underwent a very dramatic change in conformation, wrapping around the peptide, with which it forms several side chain interactions, and forming a latch between the N-and C-terminal halves of CaM (Fig. 8C) .
One of the consequences of this dramatic conformational change is the formation of an exposed surface contributed by residues in helix II (Lys 30 36 to Ile, on the other hand, had no effect on binding to or activation of MLCK. We previously reported that a similar M36L mutation in bCaM had no effect on the V max of MLCK and caused a slight reduction in affinity for the enzyme (29) . These results are not surprising because Met 36 interacts with side chains in the CaM-binding domain of the kinase (Fig. 8C) (31) . An acidic cluster (EEQ, residues 6 -8) near the N terminus has also been implicated as a requirement for maximal activation of MLCK because deletion of this tripeptide reduces the V max of smooth muscle MLCK by ϳ50% (32) . The N terminus appears to facilitate movement of bound CaM away from the vicinity of the active site. The activation of MLCK by (Ca 2ϩ ) 4 ⅐CaM, in addition to interaction with the CaM-binding domain, involves a conformational change in the kinase that results in removal of the autoinhibitory domain from the active site (17, 33) . The surface between Lys 30 and Gly 40 ( Fig. 8C ) may therefore interact with an unspecified region of MLCK distinct from the CaM-binding domain and trigger removal of the autoinhibitory domain from the active site. Mutations within this surface such as K30E and G40D could disrupt this interaction so that activation of MLCK is lost, but binding to the CaM-binding domain of MLCK is unaffected. This mechanism is consistent with the original proposal of Blumenthal and Stull (34), based on thermodynamic studies, that interactions between the external surface of CaM and skeletal muscle MLCK occur in addition to the interactions between CaM and the CaM-binding domain of the kinase and with the work of Su et al. (31) showing the importance of Thr 110 and Lys 115 , which are also located in this surface or activation domain. An alternative mechanism is also possible whereby this activation domain may be required to stabilize the conformation of (Ca 2ϩ ) 4 ⅐CaM necessary for MLCK activation without directly interacting with the kinase.
Our recent work has indicated that a distinct pool of cellular CaM is involved in activation of smooth muscle contraction (25) . This CaM is bound to the detergent-insoluble fraction, composed of the myofilaments and cytoskeleton, even in the absence of Ca 2ϩ . Consistent with these findings, it has been shown that the CaM-binding domain of MLCK can interact with apoCaM, albeit at low ionic strength (35) . Steady-state Ca 2ϩ titrations indicated that the affinity of the two C-terminal Ca 2ϩ -binding sites of CaM is markedly enhanced (K d ϭ 1.1 ϫ 10 Ϫ7 M) in the presence of the CaM-binding domain of MLCK (36) . Because the resting level of the cytosolic free [Ca 2ϩ ] in smooth muscle cells is 130 -140 nM (37, 38) , this suggests that the contractile pool of CaM consists of a mixture of (Ca 2ϩ ) 0 ⅐CaM and (Ca 2ϩ ) 2 ⅐CaM, both of which are bound to, but do not activate, MLCK (18, 25, 36) , which is itself anchored to the actin filament via its N-terminal tail (15, 16) . Following the increase in the cytosolic free [Ca 2ϩ ] in response to contractile stimuli, Ca 2ϩ diffuses to the myofilaments, where it binds to the two N-terminal Ca 2ϩ -binding sites on CaM as well as to any Ca 2ϩ -free C-terminal sites, inducing the conformational change that leads to formation of the surface containing Lys 30 and Gly 40 . We therefore conclude that formation of this surface is critical for removal of the autoinhibitory domain from the active site, resulting in activation of the kinase.
